Health · 1 views
Policy changes could make esketamine more affordable for treatment-resistant depression
The study found that measures such as price negotiation, value-based access arrangements, optimized service delivery and targeted patient selection could help make esketamine more accessible while maintaining the sustainability of the he…
AI Summary
A joint research team led by the LKS Faculty of Medicine at the University of Hong Kong, together with collaborators from the Chinese University of Hong Kong, New York University and Newcastle University, has identified that a combination of policy adjustments and service measures could improve the value and affordability of esketamine nasal spray, a novel rapid‑acting treatment for treatment‑resistant depression. The findings suggest that coordinated changes in reimbursement, pricing and delivery models may make the therapy more accessible to patients who need it.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Even symptom-free IBD patients show gut cells primed for damage, study findsContinue reading
- Hospitals could track emissions, water and waste alongside patient safetyContinue reading
- Now is the time for evidence-based, specific dietary guidance to nourish adolescentsContinue reading
- RSV admissions among infants fall sharply following vaccine rolloutContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow